Last reviewed 2026-04-20 · How we verify

GSK1325756

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nasopharyngitis
• Upper respiratory tract infection
• Back pain
• Headache
• Nausea
• Fatigue
• Malaise
• Cough
• Dyspnoea
• Hyperhidrosis
• Diarrhoea
• Vessel puncture site haematoma

Key clinical trials

• GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects (PHASE1)
• Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
• Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza (PHASE2)
• Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
• A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
• Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza (PHASE2)
• A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole (PHASE1)
• Blood Levels and Effects of GSK1325756 in Healthy Adult Volunteers Aged 40 to 80 Years Old (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.